VDAC1 and triple-negative breast carcinoma: In our previous studies, we demonstrated, both in vitro and in mouse xenograft models of human glioblastoma (U-87MG), lung cancer (A549), and triple negative breast cancer (MDA-MB-231), that silencing VDAC1 expression using human-specific siRNA (si-hVDAC1-2A) inhibited cancer cell growth [41,46,47,48,49,50].